A veteran digital and television journalist, Michelle Fox writes articles for CNBC.com and acts as a liaison between the website and CNBC television shows.
Prior to joining CNBC.com, she spent years on the broadcast side of the business, including an earlier stint at CNBC. Fox has also worked at MSNBC, Court TV and WCBS-TV in New York, where she earned an Emmy award for anticipated breaking news coverage.
Wal-Mart is doing a lot of things right, but it should spend its money on other things rather than buying back more stock, Bill Simon said.
Umer Raffat of Evercore ISI has two names at the top of his buy list — Allergan and Dermira.
Here's why Leuthold Group's Jim Paulsen thinks the market is in a "sweet spot."
The EU isn’t looking to make an example of the U.K. for its decision to leave – it is just a “very difficult” situation, Jean-Claude Trichet said.
When asked if Flexion would look to other applications for its new non-opioid drug, its CEO said, "We're absolutely thinking about it."
It would be "ill-advised" to be an aggressive buyer at these levels, Dennis Gartman told CNBC.
President Donald Trump's recent comments are making GOP strategist Ron Christie nervous – and he told CNBC he's probably not the only one.
The recent market melt-up may be in part due to the resurgence of tax reform talk, but that’s not necessarily key, Jason Ware said.
There appears to be a broken logistics process in Puerto Rico, serial entrepreneur Marcus Lemonis told CNBC on Thursday.
While Mylan's FDA approval for its generic MS drug is a big win, simple math shows investor reaction may be too enthusiastic, David Maris said.